1. |
3,3′-diindolylmethane
|
3,3′-Methylenebis(1H-indole)
|
Decreased methylation of CpG sites in the promoter region of mouse Nfe2l2
|
Suppressed mRNA and protein expression of Dnmt1, Dnmt3a, and Dnmt3b; inhibited protein expression of Hdac2 and Hdac3 |
TRAMP-C1 prostate cells |
[79] |
2. |
Apigenin
|
5,7-Dihydroxy-2-(4hydroxy-phenyl)-4H-chromen-4-one |
Decreased Nfe2l2 hyper-methylation; induced expression of miR-101, targeting Nfe2l2 mRNA |
Inhibited Dnmt1, Dnmt3a and Dnmt3b; inhibited Hdacs; induced miR101 |
Mouse epidermal JB6 P+ cells BEL-7402/ADM cells |
[80,81] |
3. |
Corosolic acid |
2α,3β-2,3-dihydroxyurs-12-en-28-oic acid |
Decreased Nfe2l2 hypermethylation; increased histone H3 lysine 27 acetylation; decreased H3 lysine 27 trimethylation |
Decreased levels of Dnmt1, Dnmt3a and Dnmt3b; reduced levels of Hdac1, Hdac2, Hdac3, Hdac4, Hdac7 and Hdac8 |
TRAMP-C1 prostate cells |
[82] |
4. |
Curcumin |
1, 7-bis (4-hydroxy-3-methoxy-phenyl)-1, 6 heptadiene-3, 5-dione |
Decreased Nfe2l2 hypermethylation |
Inhibited enzymatic activity of Dnmt enzymes |
TRAMP-C1 prostate cells |
[83] |
5. |
Delphinidin |
3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl) chromenium |
Demethylation of 15 CpG sites in the mouse Nfe2l2 promoter region |
Decreased protein expression of Dnmt1, Dnmt3a, and class I/II Hdacs |
Mouse epidermal JB6 P+ cells |
[84] |
6. |
Fucoxanthin |
3,5′-Dihydroxy-8-oxo-6′,7′-didehydro-5,5′,6,6′,7,8-hexahydro-5,6-epoxy-β,β-caroten-3′-yl acetate |
Decreased Nfe2l2 hypermethylation |
Reduced Dnmt activity |
Mouse epidermal JB6 P+ cells |
[85] |
7. |
Luteolin
|
2-(3,4dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one |
Decreased NFE2L2 hypermethylation |
Decreased expression of DNMT1, DNMT3A and DNMT3B; decreased HDAC1, HDAC2, HDAC3, HDAC6, HDAC7; reduced activities of DNMTs and HDACs; increased ten-eleven translocation 1, 2 and 3 (TET1, TET2, and TET3)
|
Human colon cancer cells and SNU-407 cells
|
[86,87] |
8. |
Pelargonidin |
3,5,7-Trihydroxy-2-(4hydroxyphenyl) chromenium |
Decreased methylated CpGs in Nfe2l2 promoter |
Decreased Dnmt1 and Dnmt3b expression; reduced levels of Hdacs 1–4 and Hdac7 |
JB6 P+ cells |
[88] |
9. |
Polydatin |
3-Hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl] phenyl β-d-glucopyranoside |
Enhanced miR-200a targeting KEAP1 to activate NRF2 signaling |
Increased miR-200a expression under high fructose induction; downregulated KEAP1 mRNA and protein |
Buffalo rat liver (BRL-3A) and human HepG2 cells |
[89] |
10. |
Reserpine
|
Methyl 18β-hydroxy-11,17α-dimethoxy-3β,20α-yohimban-16βcarboxylate 3,4,5-trimethoxybenzoate |
Decreased proportion of methylated CpG sites in the Nfe2l2 promoter |
Concentration-dependent decreased mRNA and protein expression of Dnmt1, Dnmt3a, and Dnmt3b |
JB6 P+ Cell |
[90] |
11. |
Resveratrol
|
3,4′,5-trihydroxystilbene |
Decreased methylation of the NFE2L2 promoter |
Inhibited expression and activity of DNMT1, DNMT3a, and DNMT3b; miR93 implicated |
HepG2 cells and estradiol-induced breast cancer |
[91,92] |
12. |
Sulforaphane
|
1-Isothiocyanato-4-(methanesulfinyl)butane |
CpG demethylation and histone acetylation at the Nfe2l2 promoter; lncRNA upregulation |
Inhibition of Dnmt1, Dnmt3a, Dnmt3b, Hdacs 1–5, and Hdac7; upregulated functional pseudogene NMRAL2P
|
JB6 P+ cells; TRAMP C1 cells; human colon cancer cells |
[93,94] |
13. |
Tanshinone IIA
|
1,6,6-trimethyl-8,9- dihydro-7H-naphtho [1,2-g] benzofuran-10,11-dione |
Decreased methylated CpGs in Nfe2l2 promoter; increased recruitment of RNA polymerase complex II at the NFE2L2 transcription start site |
Decreased mRNA and protein levels of HDAC1, HDAC3, and HDAC8, as well as DNMT1, DNMT3a, and DNMT3b; induced expression of TET2 |
JB6 P+ cells, human normal hepatocyte and Hepa RG cells; rifampicin-induced liver injury in mice |
[95,96] |
14. |
Taxifolin
|
(2S,3S)-2-(3,4dihydroxy-phenyl)-3,5,7-trihydroxy-2,3dihydro-4H-chromen-4-one
|
Decreased proportion of methylated CpGs in the Nfe2l2 promoter |
Reduced protein levels of Dnmt1, Dnmt3a and Dnmt3b as well as Hdacs 1, 3, 4, and 8 |
JB6 P+ cells |
[97] |
15. |
Ursolic acid |
(3β)-3-Hydroxyurs-12-en-28-oic acid |
Nfe2l2 mouse promoter demethylation; increased acetylation and K4 monomethylation of histone H3 in human cells |
Reduced DNMT1 and DNMT3a protein levels; inhibited expression of HDACs 1-3 and 8 (Class I) and HDAC 6 and 7 (Class II); induced Setd7 |
JB6 P+ cells PC3 and LnCaP cells |
[98,99] |
16. |
γ Tocopherol–rich mixture of tocopherols (γ-TmT) |
(2R)-2,5,7,8-tetramethyl-2-[ (4R,8R)-4,8,12-trimethyl-tridecyl]-6-chromanol |
Reversed hyper-methylation in the Nfe2l2 promoter |
Inhibited protein levels of Dnmt1, Dnmt3a, and Dnmt3b |
Prostate tissues of C57BL/TGN TRAMP mice |
[100] |
17. |
Z-Ligustilide |
(3E)-3-butylidene-4,5-dihydro-2-benzofuran-1-one |
Decreased methylation of the first five CpGs of the Nfe2l2 promoter |
Inhibited Dnmt activity |
TRAMP C1 cells |
[101] |